Adcetris (brentuximab vedotin)

P3, N=239, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Dec 2026 --> Jan 2026

Recent years have seen a shift away from chemotherapy with the approval of targeted therapies like mogamulizumab, brentuximab vedotin, and denileukin diftitox-cxdl. Though these novel agents have improved outcomes for patients with advanced-stage CTCL, most patients will continue to experience relapses. Emerging agents, including lacutamab, resminostat, and immune checkpoint inhibitors and biomarkers including CD5, CD70, and CD47/Sirpα represent the next frontier in maintaining durable remissions and improving quality of life (QoL) for these patients.

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.

P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P2, N=150, Active, not recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Not yet recruiting --> Active, not recruiting

P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting

After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.

P2, N=161, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Feb 2026

This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.

The introduction of BV has significantly improved real-world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.